Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBT: 2019-2024

Historic EBT for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to -$232.9 million.

  • Centessa Pharmaceuticals' EBT fell 30.43% to -$54.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$239.3 million, marking a year-over-year decrease of 51.15%. This contributed to the annual value of -$232.9 million for FY2024, which is 32.23% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its EBT stood at -$232.9 million for FY2024, which was down 32.23% from -$176.1 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' EBT registered a high of -$10.7 million during FY2020, and its lowest value of -$381.0 million during FY2021.
  • Over the past 3 years, Centessa Pharmaceuticals' median EBT value was -$217.0 million (recorded in 2022), while the average stood at -$208.7 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' EBT plummeted by 3,472.70% in 2021, and later skyrocketed by 43.05% in 2022.
  • Centessa Pharmaceuticals' EBT (Yearly) stood at -$10.7 million in 2020, then plummeted by 3,472.70% to -$381.0 million in 2021, then spiked by 43.05% to -$217.0 million in 2022, then rose by 18.81% to -$176.1 million in 2023, then crashed by 32.23% to -$232.9 million in 2024.